Abstracts Archive - Page 97 of 1683 - ATC Abstracts

2022 American Transplant Congress
EBV+ PTLD Tumor MicroRNAs Detected in Circulating Extracellular Vesicles Are Decreased in Pediatric Transplant Recipients with EBV+ PTLD
A. Sen¹, J. Enriquez¹, M. Rao¹, M. Glass¹, Y. Balachandran¹, S. Syed¹, C. Twist¹, K. Weinberg¹, S. D. Boyd¹, D. Bernstein¹, A. Trickey¹, D. Gratzinger¹, B. Tan¹, M. G. Lapasaran¹, M. A. Robien², M. Brown³, B. Armstrong⁴, M. Sever⁴, D. Desai⁵, G. Mazariegos⁶, C. Chin⁷, T. Fishbein⁸, R. S. Venick⁹, A. Tekin¹⁰, H. Zimmermann¹¹, R. U. Trappe¹², C. O. Esquivel¹, O. M. Martinez¹, S. M. Krams¹
¹Stanford U, Palo Alto, CA, ²NIH, Bethesda, MD, ³NIAID, Bethesda, MD, ⁴Rho, Durham, NC, ⁵UT Southwestern, Dallas, TX, ⁶Pittsburgh U, Pittsburgh, PA, ⁷CCHMC, Cincinnati, OH, ⁸Georgetown U, Washington, DC, ⁹UCLA, LA, CA, ¹⁰Miami U, Miami, FL, ¹¹DIAKO Ev. Diakonie-Krankenhaus, Bremen, Germany, ¹²Charité - Universitätsmedizin, Berlin, Germany
*Purpose: Post-transplant lymphoproliferative disorder (PTLD) is a serious complication of solid organ transplantation. Predisposing factors for PTLD include primary Epstein-Barr virus (EBV) infection in children,…
2022 American Transplant Congress
Disparities in Liver Transplantation in Patients with HCC Diagnosis
C. Warren¹, A. Zarrinpar²
¹Surgery, University of Florida Shands Health, Gainesville, FL, ²Surgery, University of Florida Health Shands, Gainesville, FL
*Purpose: Disparities in outcomes of hepatocellular carcinoma (HCC) have not been adequately studied, especially in the context of liver transplantation (LT). We sought to identify…
2022 American Transplant Congress
Outcomes of Sodium-Glucose Cotransporter 2 Inhibitors and Glucagon-Like Peptide-1 Receptor Agonists in Diabetic Kidney Transplant Recipients
T. S. Mahmoud¹, J. Yagan¹, A. Hasan², O. Gheith¹, M. Mostafa¹, S. Rida¹, N. El-Serwy¹, M. Shaker¹, M. Khalid¹, P. Nair¹, T. Alotaibi¹
¹Nephrology, Organ Transplant Center, Kuwait, Kuwait, ²Immunometabolism, Dasman Diabetes Center, Kuwait, Kuwait
*Purpose: The impact of the new glucose lowering therapies, sodium-glucose cotransporter 2 inhibitors (SGLT2i) and Glucagon-like peptide-1 receptor agonists (GLP-1RA), on managing patients with type…
2022 American Transplant Congress
Utility of Porcine Kidneys in Transplantation Model for Training General Surgery Residents
O. Eletta, V. Putatunda, D. Walls, C. Antwi-Buosiako, B. Perry, N. Maloney Patel, R. Pelletier, A. Bongu
Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ
*Purpose: We sought to increase the opportunities for general surgery residents to hone their vascular anastomosis skills. Accordingly, we created a kidney transplant model using…
2022 American Transplant Congress
The Prevalence of Anti-SARS-CoV-2 Antibodies After COVID-19 is Similar in Kidney Transplant Recipients to Non-Transplanted Patients, and the Clinical Severity is a Predictor of Seroconversion
L. R. Requião-Moura, R. Garcia, M. R. Nakamura, R. D. Foresto, V. Gomes, T. Ferreira, I. Meira, M. Cristelli, M. Jesus, R. Rissoni, E. Lucena, H. Tedesco-Silva, J. Medina-Pestana
Nephrology Division - Hospital do Rim, Universidade Federal de São Paulo, São Paulo, Brazil
*Purpose: To evaluate the seroconversion rate in kidney transplant recipients (KTR), compared to two non-transplanted groups of patients, and identify predictors of seroconversion in COVID-19…
2022 American Transplant Congress
Semaglutide Tolerability and Efficacy in Patients with Chronic Kidney Disease Stage 4, 5 and End Stage Renal Disease
J. J. Long, A. Lemke, V. Sudhindran, N. Pencovici, A. Kukla, T. Diwan
Mayo Clinic, Rochester, MN
*Purpose: Obesity is often a barrier to kidney transplantation (KT) due to increased perioperative risks and worse outcomes with many transplant centers setting BMI cut…
2022 American Transplant Congress
Case Times For Brain Dead Donors: Longer Is Not Better, No Impact Of Longer Case Time On Organ Yield Or OPO Performance Tier
M. J. Moritz¹, R. Hasz¹, H. Nathan¹, E. Hunt², S. Noreen³, A. Toll⁴
¹Gift of Life Donor Program, Philadelphia, PA, ²Surgery, Lehigh Valley Health Network, Allentown, PA, ³United Network for Organ Sharing, Richmond, VA, ⁴Research, United Network for Organ Sharing, Silverdale, WA
*Purpose: Having observed the steady increase in case times, we wished to examine if this has impacted organ yield*Methods: We conducted a retrospective cohort study…
2022 American Transplant Congress
The Impact Of Monoclonal Antibody Against Sars-CoV2 And Vaccination On Outcomes In Kidney Transplant Recipients With Covid-19
N. M. Ali, V. Tatapudi, R. Chand, k. Sureau, S. Mehta, R. Montgomery
NYU Langone Transplant Institute, New York, NY
*Purpose: Solid organ transplant recipients are at high risk of morbidity and mortality from coronavirus disease 2019 (COVID-19) with mortality rates as high as 30%…
2022 American Transplant Congress
Longevity Matching for Living Donor Renal Transplantation
S. Karhadkar¹, J. Dawes¹, K. Wirshup¹, J. Kolansky¹, A. Gregor¹, A. Diamond², A. DiCarlo¹
¹Temple University Hospital, Philadelphia, PA, ²-, Garnet Valley, PA
*Purpose: Living donor kidney transplantation (LDKT) continues to become a more prevalent treatment method for ESRD and is known to increase both organ availability and…
2022 American Transplant Congress
Cardiovascular Outcomes of Kidney Transplant Recipients Receiving Belatacept Compared to a Matched Tacrolimus
Y. Kim¹, J. Marvin¹, K. Belfield¹, G. Girone¹, R. Formica², E. Cohen¹
¹Pharmacy, Yale New Haven Hospital, New Haven, CT, ²Section of Nephrology, Yale School of Medicine, New Haven, CT
*Purpose: Tacrolimus (TAC), a calcineurin inhibitor (CNI), is the backbone of maintenance immunosuppression in kidney transplant recipients (KTR) but has been associated with cardiovascular (CV)…